The Federal Circuit has fully revived the patent claims for Allergan’s bowel treatment drug, Viberzi, in a recent decision. This reversal overruled a previous determination by a Delaware federal judge, who argued that the claims did not satisfy the requirements for obviousness-type double patenting or the written description. This restoration could have significant implications for Johnson & Johnson and Allergan as they navigate the complexities of intellectual property protection for their pharmaceutical products. For more details on the ruling, you can read the full Law360 article here.